BBIO Quote, Financials, Valuation and Earnings

Cytokinetics has a net margin of -143.55% compared to BridgeBio Pharma's net margin of -10220.14%. BridgeBio Pharma's return on equity of -- beat Cytokinetics's return on equity of --.

BridgeBio Pharma has a consensus price target of $59.22, signalling upside risk potential of 51.74%. On the other hand Cytokinetics has an analysts' consensus of $72.55 which suggests that it could grow by 118.99%. Given that Cytokinetics has higher upside potential than BridgeBio Pharma, analysts believe Cytokinetics is more attractive than BridgeBio Pharma.

BridgeBio Pharma has a beta of 1.104, which suggesting that the stock is 10.36% more volatile than S&P 500. In comparison Cytokinetics has a beta of 0.592, suggesting its less volatile than the S&P 500 by 40.762%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $116.6M, which are larger than Cytokinetics quarterly revenues of $1.6M. BridgeBio Pharma's net income of -$167.4M is lower than Cytokinetics's net income of -$161.4M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 57.87x versus 199.78x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of -143.55% compared to BridgeBio Pharma's net margin of -53.36%. BridgeBio Pharma's return on equity of -- beat Madrigal Pharmaceuticals's return on equity of -49.57%.

BridgeBio Pharma has a consensus price target of $59.22, signalling upside risk potential of 51.74%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $423.14 which suggests that it could grow by 50.99%. Given that BridgeBio Pharma has higher upside potential than Madrigal Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Madrigal Pharmaceuticals.

BridgeBio Pharma has a beta of 1.104, which suggesting that the stock is 10.36% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -1.074, suggesting its less volatile than the S&P 500 by 207.402%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $116.6M, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $137.3M. BridgeBio Pharma's net income of -$167.4M is lower than Madrigal Pharmaceuticals's net income of -$73.2M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 57.87x versus 19.24x for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -143.55% compared to BridgeBio Pharma's net margin of 21.63%. BridgeBio Pharma's return on equity of -- beat Pfizer's return on equity of 8.72%.

BridgeBio Pharma has a consensus price target of $59.22, signalling upside risk potential of 51.74%. On the other hand Pfizer has an analysts' consensus of $29.24 which suggests that it could grow by 21.98%. Given that BridgeBio Pharma has higher upside potential than Pfizer, analysts believe BridgeBio Pharma is more attractive than Pfizer.

BridgeBio Pharma has a beta of 1.104, which suggesting that the stock is 10.36% more volatile than S&P 500. In comparison Pfizer has a beta of 0.572, suggesting its less volatile than the S&P 500 by 42.759%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.09% to investors and pays a quarterly dividend of $0.43 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $116.6M, which are smaller than Pfizer quarterly revenues of $13.7B. BridgeBio Pharma's net income of -$167.4M is lower than Pfizer's net income of $3B. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 57.87x versus 2.19x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -143.55% compared to BridgeBio Pharma's net margin of --. BridgeBio Pharma's return on equity of -- beat Viking Therapeutics's return on equity of --.

BridgeBio Pharma has a consensus price target of $59.22, signalling upside risk potential of 51.74%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 227.4%. Given that Viking Therapeutics has higher upside potential than BridgeBio Pharma, analysts believe Viking Therapeutics is more attractive than BridgeBio Pharma.

BridgeBio Pharma has a beta of 1.104, which suggesting that the stock is 10.36% more volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.648, suggesting its less volatile than the S&P 500 by 35.236%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $116.6M, which are larger than Viking Therapeutics quarterly revenues of --. BridgeBio Pharma's net income of -$167.4M is lower than Viking Therapeutics's net income of -$45.6M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 57.87x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.